Apart from having a primary glucose-lowering effect, SGLT2 inhibitors, such as empagliflozin, also reduce bodyweight and improve metabolic health in patients with T2DM (Häring et al., 2013; Chilton et al., 2015; Davidson and Sloan, 2017). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.